Evidence map›Paper›PMID 34630840›Full record

ArticleThe Pan African medical journal2021

[Evaluation of two COVID-19 antigenic diagnostic tests:

Guy Pascal Ngaba, Ginette Claude Mireille Kalla, Jules Clément Nguedia Assob, Abdel Jelil Njouendou, Christian Nelly Jembe, Emile Télesphore Mboudou, François-Xavier Mbopi-Keou

Open access · goldAbstract readComparative Study
In one paragraph

Article in The Pan African medical journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Guy Pascal NgabaFaculté de Médecine et des Sciences Pharmaceutiques, Université de Douala, Douala, Cameroun.
Ginette Claude Mireille KallaFaculté de Médecine et des Sciences Biomédicales, Université de Yaoundé I, Yaoundé, Cameroun.
Jules Clément Nguedia AssobFaculté de Médecine et des Sciences Pharmaceutiques, Université de Douala, Douala, Cameroun.
Abdel Jelil NjouendouFaculté des Sciences de la Santé, Université de Buea, Buea, Cameroun.
Christian Nelly JembeMinistère de la Santé publique, District de santé de Deïdo, Douala, Cameroun.
Emile Télesphore MboudouHôpital Gynéco-Obstétrique et Pédiatrique de Douala, Douala, Cameroun.
François-Xavier Mbopi-KeouFaculté de Médecine et des Sciences Biomédicales, Université de Yaoundé I, Yaoundé, Cameroun.
Université de Yaoundé I · CMUniversity of Douala · CMUniversity of Buea · CM

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionthe COVID-19 pandemic causes biological diagnostic problems that remain relevant in low-income countries in general and in Cameroon in particular. Rapids tests that reliably detect SARS-CoV-2 virus antigen present themselves as an important alternative in several contexts. The objective of our study was to evaluate the diagnostic performance of two rapid diagnostic tests BIOSYNEX

methodsa cross-sectional and comparative study was carried out from April 27 to May 29, 2021 in the city of Douala in Cameroon. The samples consisted of nasopharyngeal swabs received at the molecular biology laboratory of the Douala Gyneco-obstetric and pediatric hospital, whatever their origin. The socio-demographic parameters (age, profession, football players, travelers, others), marital status, nationality), comorbidity and known status of COVID-19, were recorded on the collection sites. The main collection sites were the Deïdo Health District and the Douala Gyneco-Obstetric and Pediatric Hospital. We performed the diagnosis of COVID-19 using the rapid diagnostic test (RDT) BIOSYNEX

resultsa total of 1813 participants were included in our study, with a predominance of men (1226, 68.68 %) and the most represented age group was that of 31 to 40 years (568, 31.33 %). Most of the participants were married (888, 53.46%) and only a few had a known COVID-19 status (75, 5.47%). The two rapid tests on our study population show much closed COVID-19 prevalence values, respectively 2.03 for BIOSYNEX

Indexed as

AdolescentAdultAgedAntigens, ViralCameroonChildChild, PreschoolCOVID-19COVID-19 TestingCross-Sectional StudiesFemaleHumansInfantInfant, NewbornMaleMiddle AgedAntigens, ViralAmpliQuick® SARS-CoV-2BIOSYNEX® COVID-19 Ag BSSBIOSYNEX® COVID-19 Ag+ BSSCamerounDoualaEvaluation

Identifiers

PMID34630840
PMCPMC8486925
OpenAlexW3202943680

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.